This study was designed to evaluate the efficacy of a new florfenicol/meloxicam combination (FMC) in calves with bovine respiratory disease. A total of 90 young calves were challenged via intratracheal deposition of 108 colony-forming units of Mannheimia haemolytica. Data for 84 calves demonstrating a rectal temperature (RT) above 39.5°C and a combined total clinical score (TCS) greater than or equal to 3 were included. Calves were then randomly allocated to one of the three study groups (FMC; florfenicol/flunixin combination (FFC); or saline) and promptly treated. RT and TCS of calves treated with an FMC or FFC were consistently lower than RT and TCS of calves belonging to the control group (P<0.001). Moreover, at the end of the study, a high clinical cure rate was observed in calves treated with FMC (100 per cent) or FFC (96.6 per cent) whereas cure was limited for calves receiving saline (29.6 per cent). Interestingly, calves treated with FMC were cured without relapse more rapidly compared with calves treated with FFC (HR=1.76, P<0.05) and with a lower percentage of clinical relapse due to fever (P=0.05). These results underline the high efficacy of the FMC and are in line with the pharmacokinetic properties of florfenicol and meloxicam.
- bovine respiratory disease
Statistics from Altmetric.com
Funding This study was funded by Ceva Santé Animale.
Competing interests DA, ACV and JFC are employees of Ceva Santé Animale.
Ethics approval All experimental protocols involving animals were approved by the Moredun Research Institute Animal Experiments and Ethical Review Committee and were authorised under the UK Animals (Scientiﬁc Procedures) Act 1986.
Provenance and peer review Not commissioned; externally peer reviewed.
Presented at Preliminary results were presented as an Abstract at the 2017 European Buiatrics Forum, Bilbao, 4–6 October 2017.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.